pneumonia (12%), bone and joint infections (11%), bloodstream infections (10%), urinary tract 23 infections (10%), surgical site infections (5%) and skin and soft tissue infections (4%). Of them, 24 68 received regular outpatient follow-up visits at our infectious disease clinic, where the majority 25 of patients (91%) were successfully treated with ertapenem by the end of therapy. Of the 6 26 patients who experienced clinical failure, 2 had adverse events leading to discontinuation of 27 therapy and 4 required additional source control for clinical success. In addition, two patients had 28 recurrent infection at 6 months. 
RESULTS

81
Indications for post-discharge ertapenem therapy. A total of 306 unique patients who 82 received ertapenem outpatient therapy were identified during the study period. There had been a 83 steady increase in the use of outpatient ertapenem therapy with 59, 73,116 and 58 patients 84 discharged on ertapenem in 2010, 2011, 2012 and the first 6 months of 2013, respectively. The 85 most common indication for outpatient ertapenem therapy in this all study group was intra-86 abdominal infections (n=116; 38%), followed by pneumonia (n=36; 12%), bone and joint 87 infections (n=35; 11%), bloodstream infections (n=31; 10%), urinary tract infections (n=31; 88 10%), surgical site infections (n=14; 5%) and skin and soft tissue infections (n=12; 4%). 89
Among the 306 patients in the all study group, 238 patients were excluded due to various 90 reasons: 157 patients received ertapenem therapy for less than 2 weeks, 43 patients had follow-91 up visits with their primary care physicians, while 38 were discharged to long-term healthcare 92 facilities and were followed up by physicians at the respective facilities. After their exclusion, 68 93 patients were identified as having received at least 2 weeks of ertapenem and had regular 94 outpatient follow-up visits at the Infectious Disease Clinic and constituted the OPAT group. The 95 clinical outcomes of these patients are summarized in Forty-two patients (91%) underwent surgical intervention during hospital stay, with 37 having a 113 drain placement and 5 having incision and drainage of abscesses. Twenty-two (48%) were 114 started on ertapenem in hospital, while 24 (52%) were switched from another agent to ertapenem 115 upon discharge. Among these 24 patients, 15 and 9 had received piperacillin-tazobactam and 116 ampicillin-sulbactam before discharge, respectively, with a median duration of 7 days (range, 2 -117 15). Eight patients (17%) were discharged on a second Gram-positive agent in addition to 118 ertapenem (6 and 2 on vancomycin and daptomycin, respectively). Forty-two (91%) and 4 (9%) 119 patients were discharged to home and nursing home, respectively. The first post-hospitalization 120 follow-up at the Infectious Disease Clinic was at a median of 3 weeks after discharge (range, 2 -121 
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Our study found that ertapenem is increasingly utilized in post-hospitalization, outpatient settings 213 for various infectious disease diagnoses at our center, which is consistent with a previous report 214 (7). The overall clinical success rate among patients who completed the course of ertapenem was 215 91% (62/68), while 3% (2/68) had discontinuation of ertapenem therapy due to adverse events 216 and another 6% (4/68) had clinical failure at the end of ertapenem therapy requiring additional 217 surgical intervention for source control. Additionally, 3% (2/68) had recurrent disease at 6 218 months. The most common indications for ertapenem therapy were intra-abdominal infections 219 and osteomyelitis. The clinical success rate was 91% for intra-abdominal infections, which is 220 slightly higher than the rates reported in previous studies (12, 13). The difference may be due to 221 higher proportion of patients who underwent surgical interventions for source control in our 222 study (91%). The success rate for osteomyelitis was 83%, which is consistent with a previous 223 study (14) . As would be expected, the median duration of ertapenem therapy was significantly 224 longer for patients with osteomyelitis than those with other diagnoses (8 vs 4 weeks, P=0.008). 225
Another noteworthy finding was that therapy for 46% of the patients (31/68) were changed from 226 another agent to ertapenem upon discharge. 227
Adverse events in patients treated with ertapenem were relatively rare, which was 228 consistent with previous studies (12, 14) . One patient developed a skin rash within 2 weeks of 229 ertapenem therapy resulting in its discontinuation. Ertapenem use has been associated with skin 230 rash which usually occurs several weeks into therapy (1). Another patient developed significant 231 elevation of transaminase levels after 2 weeks of ertapenem therapy. This was a transient rise and 232 returned to normal levels after its discontinuation. Two other patients developed mild elevation 233 in transaminase levels that did not require discontinuation and normalized after completion of 234 on November 12, 2017 by guest http://aac.asm.org/ Downloaded from ertapenem therapy. Transaminase elevation is a known side effect of ertapenem but has not been 235 associated with clinical consequences (1, 3) . 236
Our study is limited by its observational nature and relatively small number of patients 237 from a single center, as we limited our analysis to patients who had regular follow-up in our own 238 clinic post-discharge from the hospital. In addition, it was a single arm study and there was no 239 comparator group. 240
In conclusion, ertapenem is increasingly utilized for a broad range of bacterial infections 241 which require long-term therapy at our center. The data presented here provide insights into the 242 efficacy and safety of long-term ertapenem therapy in OPAT settings. 
